UPDATE: Fireside chat will be held on Tuesday, April 12, 2022, from 10:15 a.m. to 10:55 a.m. EDT
NEW HAVEN, Conn., April 11, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced an updated time slot for their fireside chat at the 21st Annual Needham Virtual Healthcare Conference. Jennifer Good, President and Chief Executive Officer, along with Dr. Bill Forbes, Chief Development Officer, will participate in a fireside chat on Tuesday, April 12, 2022, at 10:15 a.m. ET.
A live webcast of the fireside chat will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About CANALInterim analysis results from the Phase 2 Cough And NALbuphine (CANAL) trial were statistically significant on the primary efficacy endpoint with a 77% reduction in daytime cough frequency from study baseline for Haduvio, demonstrating a 52% placebo-adjusted reduction in the geometric mean percent change (p